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Hypertension is the most common modifiable risk factor for cardiovascular disease (CVD)1 
and is a leading cause of death globally.2 Hypertension and CVD share common antecedent 
risk factors which include physical inactivity, obesity, and excess alcohol intake.3 Though 
these established risk factors explain a large proportion of hypertension risk, its 
pathogenesis is still not fully established as it appears other additional life-style and genetic 
factors may be involved. There is therefore a need to identify and evaluate putative risk 
factors that may increase our knowledge of hypertension development, may have causal or 
predictive relevance, and which will help develop preventive and management strategies. 
 
There is a wealth of evidence suggesting that inflammatory processes play a key role in the 
pathogenesis of coronary heart disease (CHD), which is the major manifestation of CVD.4 5 It 
is reported that the process of atherosclerosis is characterised by a chronic, low-grade 
inflammatory process.6 Indeed, both “upstream” (pro-inflammatory cytokines such as 
interleukin-1 (IL-1), IL-6, IL-18, tumour necrosis factor-α (TNF-α)) and “downstream” 
biomarkers (eg, C-reactive protein (CRP), fibrinogen) (Table 1) have consistently been 
demonstrated to be associated with CHD risk in several epidemiological studies (Table 2). 
Many “upstream” markers regulate the hepatic synthesis of “downstream” markers such as 
CRP and fibrinogen; however, IL-6 plays a central role in regulating the downstream 
inflammatory responsible for initiation and progression of the atherosclerotic process. Given 
the close link between hypertension and CVD and the established relationship between 
inflammation and CVD, it is plausible that inflammation would be linked to the risk of 
hypertension. 
 
Based on the rationale that systematic inflammation may play a role in the development of 
hypertension and given the inconsistent evidence in the existing literature, Jayedi and 
colleagues performed a first literature-based systematic meta-analysis to assess the 
associations of circulating inflammatory markers with the risk of hypertension.7 Using 
prospective and retrospective cohort designs, the authors evaluated the associations of 
standard CRP, high-sensitivity CRP (hsCRP), IL-6 and IL-1β with hypertension risk. Where 
there was sufficient relevant data, the authors also performed a dose-response meta-
analysis using restricted cubic splines. In total, 21 unique studies comprising of >140, 000 
participants and >20,000 hypertension cases were included in the review.7  Increased levels 
of CRP, hsCRP and IL-6 were each associated with an increased risk of hypertension, and 
these were consistent with linear dose-response relationships. In pooled analysis of three 
studies, there was no evidence of an association between IL-1β and hypertension. The 
magnitude of the effect of IL-6 was greater than that associated with CRP or hsCRP, though 
direct comparisons could not be performed. In addition, the associations of hsCRP and IL-6 
with hypertension risk were not statistically significant when the studies were restricted to 
those results that controlled for body mass index (BMI). The authors attributed these findings 
to the limited number of studies available for pooling. However, given that adiposity is 
associated with increased systematic inflammation and there was no evidence that the 
association between CRP and hypertension was dependent on BMI, there remained the 
question of to what degree does obesity mediate the association between inflammation and 
hypertension.  
 
The strengths of this meta-analysis include the comprehensive assessment of various 
inflammatory markers, employment of standardised risk estimates from all potential 
contributing studies to allow a consistent combination of estimates across studies, 
exploration of heterogeneity and several sensitivity analyses, subgroup analyses, and 
assessment of the dose-response relationships.7  The limitations included (i) the restricted 
number of studies available for pooling for the majority of inflammatory biomarkers; (ii) the 
use of observational designs which are characterised by residual confounding, regression 
dilution bias, and do not establish causality; (iii) substantial between study heterogeneity in 
some of the comparisons; and (iv) the inability to show the impact of adjustment for all 
potential confounders and also combine models in studies that adjusted for the same set of 
confounders, because of the varying degree of adjustments across individual studies. In light 
of the limitations, the authors called for caution when interpreting the results and 
recommended more research to elucidate the role of the evaluated inflammatory markers in 
the prevention and management of hypertension, with specific focus on whether they could 
be used as valuable screening tests for high-risk individuals.  
 
In recent years, the assessment of cardiorespiratory fitness (CRF) has achieved significant 
clinical merit and is considered to be a vital part of CVD risk assessment. The growing body 
of evidence should be an impetus for all health care providers to incorporate CRF 
improvement as a high priority in the overall clinical treatment approach for patients with 
CVDs. Levels of CRF level have been shown to be strongly related to various clinical 
characteristics, including age, sex, body composition, quantity and quality of physical 
activity, smoking, inflammation and blood pressure. Physical exercise produces a short-term, 
inflammatory response, whereas regular exercise training studies demonstrate a long-term 
“anti-inflammatory” effect. This anti-inflammatory response may partly contribute to the 
beneficial effects of habitual physical activity on CVD outcomes including hypertension. In 
our previous study of inflammation, CRF, and hypertension,8 we suggested that high CRF 
may attenuate the association between CRP and incident hypertension, especially among 
those with initially elevated CRP levels. Though there has been controversy regarding 
whether or not exercise training may reduce CRP levels independent of weight loss; clear 
evidence indicates that physical activity, improved CRF, and exercise training are associated 
with reductions in inflammation and CVD outcomes in both primary and secondary 
prevention populations.9 
 
Despite some of the limitations, the current findings of Jayedi and colleagues are very 
relevant and may have several clinical implications.7  They underscore potentially 
deleterious roles of increasing levels of CRP, hsCRP and IL-6 on the future risk of 
hypertension in the general population and are quite consistent with prior work in the arena 
of CVD. Unlike studies of CVD outcomes which have shown IL-1β, a ligand of the IL-1 
family, to play a role in the pathogenesis of CVD;10 the current meta-analysis of cohort 
studies demonstrated no evidence of an association between IL-1β and hypertension. The 
graded positive increase in hypertension risk with increasing levels of these inflammatory 
markers as well as the consistency of some of the associations, suggests causality; 
however, to demonstrate this requires robust evidence from randomised controlled trials 
(RCTs). Given the current evidence that both “upstream” and “downstream” inflammatory 
markers are associated with hypertension risk, supports the notion that the inflammation 
cascade may represent a potential causal therapeutic target. It has been reported that 
activation of the IL-1, IL-6, TNF-α pathway results in elevated levels of hepatic acute phase 
proteins, which include CRP, fibrinogen, and plasminogen activator inhibitor type-1.11 
Significant progress has been made in the arena of CVD using RCTs to test the 
inflammatory hypothesis of atherothrombosis using these pathways.11 Canakinumab and 
methotrexate, two anti-inflammatory agents, inhibit production of IL-1, IL-6, and TNF-α as 
well as hepatic production of acute-phase proteins such as CRP.11 In the recently published 
Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), canakinumab at 
doses of either 150 mg or 300 mg administered once every 3 months resulted in a 39% 
reduction in hsCRP and a 15% reduction in major adverse cardiovascular events when 
compared with placebo.12 However, canakinumab was associated with a higher incidence of 
fatal infections. Anti-inflammatory therapies may hold some early promise for CVD 
prevention and treatment; but would this be applicable for prevention and treatment of 
hypertension? It is still too early to say so as the current evidence is mostly based on 
observational data only. Whether inflammatory markers are more than just risk markers for 
hypertension needs to be resolved in future studies. 
 
We appreciate and applaud the efforts of the authors for pooling the available evidence on 
inflammation and hypertension together. Indeed, as the authors have acknowledged in their 
conclusions, further work on inflammation and hypertension is needed. Other inflammation-
related markers such as fibrinogen, TNF-α, leucocyte count, and albumin need to be 
evaluated. Due to the limited number of studies available for pooling of individual data from 
different populations, large-scale studies are still required to confirm current findings. In the 
absence of RCTs, Mendelian randomisation studies of potential genetic variants related to 
levels of these inflammatory markers may provide another route to add knowledge on the 
causal relevance of inflammatory markers in the aetiology of hypertension. Though common 
“downstream” markers such as CRP and fibrinogen have been disregarded as causal 
mediators of CHD development, there is data to suggest that a causal relationship may exist 
between the “upstream” inflammatory markers and CHD, which is based on the findings that 
the genetic variant in the IL-6 receptor signalling pathway is associated with lifelong graded 
decreases in CRP and fibrinogen concentrations, as well as proportionate decreases in CHD 
events.13 14 Whiles we await more convincing evidence on the potential relevance of 
inflammatory pathways in hypertension prevention, lifestyle measures such as engaging in 
regular physical activity; maintaining a good CRF level and healthy body weight; salt 
restriction; limitation of alcohol consumption; high consumption of vegetables and fruits; a 
low-fat diet; and elimination of smoking should remain the cornerstone for the primary 
prevention of hypertension.  
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 Table 1. “Upstream” and “downstream” markers of inflammation 
“Upstream” biomarkers “Downstream” biomarkers 
  
Interleukin-1 C-reactive protein 
Interleukin-6 Fibrinogen 
Interleukin-8 Albumin 
Interleukin-18 Leucocyte count 
Tumour necrosis factor-α Plasma and serum viscosity 
Matrix metalloproteinase-9 Alpha1-antitrypsin 
Soluble CD40 ligand Alpha2-macroglobulin 
 Lipoprotein-associated phospholipase A2 
 Plasminogen activator inhibitor type-1 
 Amyloid A protein 
 Monocyte chemoattractant protein 1 
 Haematocrit 
 Erythrocyte sedimentation rate 
 von Willebrand factor 
 
  
Table 2. Meta-analyses of prospective studies of inflammatory markers and cardiovascular 
outcomes 
Author, year of 
publication 
[reference] 
Inflammation 
marker 
Outcome No. of 
participants 
No. of 
cases 
Combined risk 
(95% CI) 
Risk comparison 
reported 
       
Danesh, 1998 [1] Fibrinogen CHD NR 4,018 1.80 (1.60-2.00) Top vs bottom third 
 CRP CHD NR 1,053 1.70 (1.40-2.10)  
 Albumin CHD NR 3,770 1.50 (1.30-1.70)  
 Leucocyte count CHD NR 7,229 1.50 (1.40-1.60)  
Danesh, 2000 [2] Haematocrit CHD NR 8020 1.16 (1.05-1.29) Top vs bottom third 
 Plasma viscosity CHD NR 1278 1.57 (1.34-1.85)  
 ESR CHD NR 1703 1.33 (1.15-1.54)  
Danesh, 2005 [3] Fibrinogen CHD 154,211 7,118 2.42 (2.24-2.60) Per 1g/l increase in 
usual fibrinogen level 
  Stroke  2,775 2.06 (1.83-2.33)  
  CVD  992 2.35 (2.21-2.49)  
       
Danesh, 2008 [4] IL-6 CHD 24,768 5,730 3.34 (2.45-4.56) Per 2-SD increase in 
usual IL-6 levels 
Kaptoge, 2010 [5] CRP CVD deaths 136,912 3,430 1.82 (1.66-2.00) Per 1-SD higher 
usual CRP levels 
  CHD 91,990 5373 1.37 (1.27-1.48)  
  Ischaemic stroke 60,763 1931 1.27 (1.15-1.48)  
Kaptoge, 2014 [6] IL-6 CHD 1514 833 1.25 (1.19-1.32) Per 1-SD higher 
levels 
 IL-18    1.13 (1.05-1.20)  
 MMP-9    1.07 (0.97-1.19)  
 sCd40L    1.07 (0.95-1.21)  
 TNF-α    1.17 (1.09-1.25)  
Kunutsor, 2016 [7] Fibrinogen SCD 25,553 388 2.07 (1.59-2.69) Per 1-SD higher 
usual fibrinogen 
levels 
 
CHD, coronary heart disease; CI, confidence interval; CRP, C-reactive protein; CVD, cardiovascular disease; IL, interleukin; 
MMP-9, matrix metalloproteinase-9; SCD, sudden cardiac death; SD, standard deviation; sCd40L, Soluble CD40 ligand; TNF, 
tumour necrosis factor 
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